

# Thomas Botton

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1954673/thomas-botton-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

2,276  
citations

15  
h-index

21  
g-index

21  
ext. papers

2,947  
ext. citations

11.3  
avg, IF

4.71  
L-index

#	Paper	IF	Citations
20	Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 64	9.8	4
19	Comment on "Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy" <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 524-525	3.9	
18	Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. <i>Cell Reports</i> , <b>2019</b> , 29, 573-588.e7	10.6	30
17	Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in Mutant Cholangiocarcinoma Harboring a Novel Fusion. <i>Oncologist</i> , <b>2018</b> , 23, 998-1003	5.7	2
16	Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. <i>Cancer Cell</i> , <b>2018</b> , 34, 56-68.e7	24.3	54
15	CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. <i>PLoS Computational Biology</i> , <b>2016</b> , 12, e1004873	5	672
14	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. <i>Cancer Cell</i> , <b>2016</b> , 29, 805-819	24.3	110
13	NTRK3 kinase fusions in Spitz tumours. <i>Journal of Pathology</i> , <b>2016</b> , 240, 282-290	9.4	95
12	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , <b>2015</b> , 47, 1194-9	36.3	177
11	Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 607-10	4.5	47
10	Activating MET kinase rearrangements in melanoma and Spitz tumours. <i>Nature Communications</i> , <b>2015</b> , 6, 7174	17.4	98
9	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. <i>Nature Communications</i> , <b>2014</b> , 5, 3116	17.4	394
8	Melanoma BRAF fusions--letter. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6631	12.9	8
7	Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. <i>Pigment Cell and Melanoma Research</i> , <b>2013</b> , 26, 845-51	4.5	93
6	Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. <i>Cell Death and Disease</i> , <b>2011</b> , 2, e199	9.8	218
5	Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. <i>Oncogene</i> , <b>2011</b> , 30, 2307-18	9.2	159
4	Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. <i>Cell Death and Differentiation</i> , <b>2011</b> , 18, 109-21	12.7	27

- 3 Rac1 dynamics in the human opportunistic fungal pathogen *Candida albicans*. *PLoS ONE*, **2010**, 5, e15400, 3-7 12
- 2 In vitro and in vivo anti-melanoma effects of cigitazone. *Journal of Investigative Dermatology*, **2009**, 129, 1208-18 4-3 43
- 1 CNVkit: Copy number detection and visualization for targeted sequencing using off-target reads 9